Finasteride News and Research

RSS
Finasteride is a synthetic antiandrogen which acts by inhibiting type II 5-alpha reductase, the enzyme that converts testosterone to dihydrotestosterone (DHT). It is used as a treatment in benign prostatic hyperplasia (BPH) in low doses, and prostate cancer in higher doses. Finasteride competitively binds to and inhibits steroid type II 5-alpha-reductase in the prostate gland, liver, and skin, thereby interfering with the enzymatic conversion of testosterone to 5-dihydrotestosterone (DHT) and reducing serum DHT levels. The reduction in serum DHT levels results in diminished stimulation of androgen receptors in the nuclei of prostate cells and, so, diminished prostate cell proliferation.
Study evaluates CaP risk among finasteride users

Study evaluates CaP risk among finasteride users

Placebo effect in the pharmacologic treatment of patients with lower urinary tract symptoms

Placebo effect in the pharmacologic treatment of patients with lower urinary tract symptoms

Predictive model of prostate cancer risk

Predictive model of prostate cancer risk

Finasteride combined with oral contraceptives may improve female hair loss

Finasteride combined with oral contraceptives may improve female hair loss

No single PSA level ensures safety from prostate cancer risk

No single PSA level ensures safety from prostate cancer risk

Finasteride prevents prostate cancer

Finasteride prevents prostate cancer

Study to compare prostate surgery and drugs

Study to compare prostate surgery and drugs

Men with low prostate specific antigen levels on screening tests can still have prostate cancer

Men with low prostate specific antigen levels on screening tests can still have prostate cancer

FDA Approves PROSCAR® Combined With Doxazosin to Reduce the Risk of Benign Prostatic Hyperplasia Symptoms

FDA Approves PROSCAR® Combined With Doxazosin to Reduce the Risk of Benign Prostatic Hyperplasia Symptoms

Study suggests ways to prevent prostate cancer

Study suggests ways to prevent prostate cancer